Newsroom

Featured Stories

NYMC Administers First Novel Inhaled mRNA Therapy for Cystic Fibrosis in the U.S.

The First Dose of RCT2100 was Successfully Administered to a Patient with Cystic Fibrosis

New York Medical College (NYMC), in collaboration with ReCode Therapeutics, a clinical-stage genetic medicines company, administered the first U.S. dose of RCT2100 — a novel investigational inhaled messenger RNA (mRNA) therapy for people with cystic fibrosis (CF). The clinical trial, which will assess the safety and tolerability of RCT2100, will provide new hope for people who do not respond to existing CFTR modulator treatments. While there are currently 13 clinical trial sites for RCT2100 throughout the country, this was the first dose to be successfully administered in the United States.